April 04, 2019

Deal Snapshot: Novartis & IFM Therapeutics

Median deal values by quarter


  • Upfront: USD 310M
  • Milestones: USD 1265M
  • Total Deal Value: USD 1575M
  • Royalties: None disclosed

Novartis Key BD Contacts

  • Global Head of Business Development & Licensing, Immunology & Dermatology | Gerrard Terlouw
  • Vice President, Global Head of NIBR Business Development and Licensing | Prakash Raman
  • Executive Director, Business Development & Licensing | Laura Gold Ripin

Novartis Deal Activity by Therapeutic Area (Last 3 Years)

Recent deal activity by disease area

Recent In-Licensing Deals and Acquisitions:

Novartis Pipeline Composition

Pipeline composition, disease areas

Novartis Lead Immunology Assets

Asset Indication Stage
ligelizumab (QGE031) Chronic spontaneous urticaria / chronic idipathic urticaria Phase III
iscalimab (CFZ533) Solid organ transplantation Phase II
LJC242 (tropifexor/cenicriviroc) Non-alcoholic steatohepatitis Phase II
lanalumab (VAY736) Primary Sjogren's syndrome Phase II

Business profiles tailored to your asset.